keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/28078646/mucosal-healing-in-ulcerative-colitis-a-comprehensive-review
#1
REVIEW
Pedro Boal Carvalho, José Cotter
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of remission and periods of relapse. Patients often present with symptoms such as rectal bleeding, diarrhea and weight loss, and may require hospitalization and even colectomy. Long-term complications of UC include decreased quality of life and productivity and an increased risk of colorectal cancer. Mucosal healing (MH) has gained progressive importance in the management of UC patients. In this article, we review the endoscopic findings that define both mucosal injury and MH, and the strengths and limitations of the scoring systems currently available in clinical practice...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28070861/efficacy-and-safety-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-patients-stratified-by-age
#2
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch
INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. METHODS: Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years...
January 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28042931/retraction-notice-to-ps124-efficacy-and-safety-of-induction-dosing-of-vedolizumab-for-reducing-biliary-inflammation-in-primary-sclerosing-cholangitis-psc-in-individuals-with-inflammatory-bowel-disease-j-hepatol-64-2016-s199
#3
B Eksteen, J Heatherington, J Oshiomogo, R Panaccione, G Kaplan, S Ghosh
No abstract text is available yet for this article.
January 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/27971341/a-qualitative-comparison-of-german-and-uk-health-technology-assessments-vedolizumab-case-study
#4
T Krieger
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27960557/the-biologics-of-ulcerative-colitis
#5
Fabio Salvatore Macaluso, Sara Renna, Ambrogio Orlando, Mario Cottone
Tumor necrosis factor α inhibitors dramatically changed the management of moderate-to-severe phenotypes of ulcerative colitis. The recent incoming of vedolizumab, which targets gut-specific leukocyte trafficking, provides a new biologic option for these patients. Areas covered: This review focuses on the rationale of use, efficacy, and safety profile of all biologics currently approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of ulcerative colitis, including tumor necrosis factor α inhibitors (Infliximab and biosimilars, adalimumab, and golimumab), and the more recent vedolizumab...
February 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27930413/efficacy-of-vedolizumab-in-patients-with-antibiotic-and-anti-tumor-necrosis-alpha-refractory-pouchitis
#6
Jessica Philpott, Jean Ashburn, Bo Shen
No abstract text is available yet for this article.
January 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27930408/vedolizumab-as-induction-and-maintenance-therapy-for-crohn-s-disease-in-patients-na%C3%A3-ve-to-or-who-have-failed-tumor-necrosis-factor-antagonist-therapy
#7
Bruce E Sands, William J Sandborn, Gert Van Assche, Milan Lukas, Jing Xu, Alexandra James, Brihad Abhyankar, Karen Lasch
BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population)...
January 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27917076/the-cost-effectiveness-of-vedolizumab-for-inflammatory-bowel-disease-a-review-of-the-current-literature
#8
Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F Steinlauf, Ellen J Scherl
The United States spends a greater share per gross domestic product on health care than any other developed country in the world. Cost-conscious, high-value care has an important role in the practice of medicine. Inflammatory bowel disease (IBD) affects 1.6 million people in the United States and is responsible for significant health care costs, with estimates as high as $31.6 billion annually, a large portion of which is attributable to the use of biologic therapies. As the number of therapeutic targets for IBD expands, gastroenterologists can anticipate the arrival of novel therapeutic agents on the market, and these may carry significant costs...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27908448/vedolizumab-as-a-successful-treatment-of-ctla-4-associated-autoimmune-enterocolitis
#9
Alexander A Navarini, Petr Hruz, Christoph T Berger, Tie Zheng Hou, Charlotte Schwab, Annemarie Gabrysch, Rebecca Higgins, Natalie Frede, Barbara-Christina Padberg Sgier, Olle Kämpe, Anne-Valérie Burgener, Florian Marquardsen, Fabian Baldin, Marc Bigler, Anne Kistner, Annaise Jauch, Olivier Bignucolo, Benedikt Meyer, Fabian Meienberg, Matthias Mehling, Lukas T Jeker, Ingmar Heijnen, Thomas D Daikeler, Jan-Olaf Gebbers, Bodo Grimbacher, David M Sansom, Raphael Jeker, Christoph Hess, Mike Recher
No abstract text is available yet for this article.
November 22, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27899374/an-induction-or-flare-of-arthritis-and-or-sacroiliitis-by-vedolizumab-in-inflammatory-bowel-disease-a-case-series
#10
G Varkas, K Thevissen, G De Brabanter, L Van Praet, F Czul-Gurdian, H Cypers, J De Kock, P Carron, M De Vos, P Hindryckx, J Arts, I Vanneuville, P Schoenaers, B Claerhout, M Abreu, F Van den Bosch, D Elewaut
BACKGROUND: In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the α4β7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of α4β7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis...
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27890854/association-between-low-trough-levels-of-vedolizumab-during-induction-therapy-for-inflammatory-bowel-diseaseswith-need-for-additional-doses-within-6-months
#11
Nicolas Williet, Gilles Boschetti, Marion Fovet, Thomas Di Bernado, Pierre Claudez, Emilie Del Tedesco, Camille Jarlot, Leslie Rinaldi, Anne Berger, Jean-Marc Phelip, Bernard Flourie, Stéphane Nancey, Stéphane Paul, Xavier Roblin
BACKGROUND & AIMS: We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin alpha 4 beta 7, during the induction phase of treatment can determine whether patients will need additional doses (optimization of therapy) within the first 6 months. METHODS: We conducted an observational study of 47 consecutive patients with Crohn's disease (CD; n=31) or ulcerative colitis (UC; n=16) who had not responded to 2 previous treatment regimens with antagonists of tumor necrosis factor and were starting therapy with vedolizumab at 2 hospitals in France, from June 2014 through April 2016...
November 24, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27888861/inflammatory-bowel-disease-in-digestive-disease-week-2016-advances-in-epidemiology-follow-up-treatment-monitoring-optimisation-and-individual-tailoring-and-colon-cancer-prevention
#12
Santiago García-López
In Digestive Disease Week 2016, interesting data were presented on the eventual role of certain foods in inflammatory bowel disease, although the value of these data is relative. Also of interest were epidemiological studies, of which several analysed the natural history of the disease. Some presentations dealt with the search for individual predictive factors, a pressing need in clinical practice. Unfortunately, some of the findings presented were of dubious value. A study suggesting that a simple parameter as increased blood monocytes could be a clear predictive factor of poor outcome could perhaps be highlighted (the results were striking but had multiple limitations)...
September 2016: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/27864657/erratum-to-vedolizumab-therapy-is-associated-with-an-improvement-in-sleep-quality-and-mood-in-inflammatory-bowel-diseases
#13
Betsy W Stevens, Nynke Z Borren, Gabriella Velonias, Grace Conway, Thom Cleland, Elizabeth Andrews, Hamed Khalili, John J Garber, Ramnik J Xavier, Vijay Yajnik, Ashwin N Ananthakrishnan
No abstract text is available yet for this article.
November 18, 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27862107/systematic-review-with-meta-analysis-comparative-efficacy-of-immunosuppressants-and-biologics-for-reducing-hospitalisation-and-surgery-in-crohn-s-disease-and-ulcerative-colitis
#14
REVIEW
E J Mao, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course leading to hospitalisation and surgery. The ability of existing therapies to alter disease course is not clearly defined. AIM: To investigate the comparative efficacy of currently available inflammatory bowel disease (IBD) therapies to reduce hospitalisation and surgery. METHODS: We conducted a systematic review in MEDLINE/PubMed for randomised controlled trials (RCT) published between January 1980 and May 2016 examining efficacy of biological or immunomodulator therapy in IBD...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27859410/effects-of-vedolizumab-on-health-related-quality-of-life-in-patients-with-ulcerative-colitis-results-from-the-randomised-gemini-1-trial
#15
B G Feagan, H Patel, J-F Colombel, D T Rubin, A James, R Mody, K Lasch
BACKGROUND: Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM: To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS: Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to calculate mean differences between the vedolizumab and placebo groups in changes from baseline to week 52 for 3 HRQL instruments: The Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Health Survey (SF-36), and EQ-5D...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27832357/emerging-biologics-in-inflammatory-bowel-disease
#16
REVIEW
Heyson Chi-Hey Chan, Siew Chien Ng
Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in those refractory to conventional medications. Anti-tumor necrosis factor (anti-TNF) agents are the most commonly used biologic agents. However, some patients may not have an initial response to anti-TNF therapy, and one-third will develop loss of response over time. Anti-TNF drugs can also be associated with side effects. In addition, the use of biologics is currently limited by their cost, especially in developing countries...
November 10, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27802155/effect-of-vedolizumab-anti-%C3%AE-4%C3%AE-7-integrin-therapy-on-histological-healing-and-mucosal-gene-expression-in-patients-with-uc
#17
Ingrid Arijs, Gert De Hertogh, Bart Lemmens, Leentje Van Lommel, Magali de Bruyn, Wiebe Vanhove, Isabelle Cleynen, Kathleen Machiels, Marc Ferrante, Frans Schuit, Gert Van Assche, Paul Rutgeerts, Severine Vermeire
OBJECTIVE: Lymphocyte recruitment to the inflamed gut is increased in UC. Inhibition of this cell trafficking by vedolizumab (VDZ) was successful in inducing and maintaining remission and in induction of endoscopic mucosal healing. There are no data on histological healing with VDZ. We studied histological changes following VDZ therapy and compared gene expression in patients with UC before and after therapy. DESIGN: Forty-one patients with UC from GEMINI I and LTS were studied before and at three time points (weeks 6/12/52) following VDZ therapy...
October 7, 2016: Gut
https://www.readbyqxmd.com/read/27796768/vedolizumab-therapy-is-associated-with-an-improvement-in-sleep-quality-and-mood-in-inflammatory-bowel-diseases
#18
Betsy W Stevens, Nynke Z Borren, Gabriella Velonias, Grace Conway, Thom Cleland, Elizabeth Andrews, Hamed Khalili, John G Garber, Ramnik J Xavier, Vijay Yajnik, Ashwin N Ananthakrishnan
INTRODUCTION: Poor sleep, depression, and anxiety are common in patients with inflammatory bowel diseases (IBD) and associated with increased risk of relapse and poor outcomes. The effectiveness of therapies in improving such psychosocial outcomes is unclear but is an important question to examine with increasing selectivity of therapeutic agents. METHODS: This prospective cohort enrolled patients with moderate-to-severe CD or UC starting biologic therapy with vedolizumab or anti-tumor necrosis factor α agents (anti-TNF)...
January 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27777897/chronic-cholestatic-liver-injury-attributable-to-vedolizumab
#19
Jonathan G Stine, Jennifer Wang, Brian W Behm
Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.
September 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/27777142/targeting-integrin-%C3%AE-4%C3%AE-7-in-steroid-refractory-intestinal-graft-versus-host-disease
#20
Yngvar Fløisand, Knut E A Lundin, Vladimir Lazarevic, Jørn Dehli Kristiansen, Liv T N Osnes, Geir E Tjønnfjord, Henrik Mikael Reims, Tobias Gedde-Dahl
Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.
January 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"